Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Technology appraisal guidance
Reference number: TA212
Published: 15 December 2010

Colorectal cancer (metastatic) - bevacizumab: patient access scheme template submitted by Roche

Please see the Roche response to the ACD for the following appendices to the Patient Access Scheme Template:

Operating cost of APAS
APAS administration cost calculations

This page was last updated: 19 August 2010